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30K protein, derived from silkworm hemolymph (SH), was known 
as having many properties. From 30K family (30Kc6, 30Kc12, 
30Kc19, 30Kc21, and 30Kc23), 30Kc6 plays role for anti-apoptosis. 
When the cells were transfected with 30Kc6, the cells had higher 
viability in stress condition. Also, these property of 30Kc6 could 
increase the productivity of antibody, recombinant interferon-β, and 
human erythropoietin (EPO). The mechanism of 30Kc6 for anti-
apoptosis was due to prevent Bax binding on mitochondria. The other 
30K protein, 30Kc19, has reported the properties of cell-penetrating 
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and enzyme-stabilizing. Cell-penetrating peptide (Pep-c19) of 
30Kc19 could enter cells by forming dimer. Also, 30Kc19 stabilized 
enzyme by crowd effect. Recent, 30Kc19 protein was reported 
enhancing soluble expression for transcription factors. 
The objective of this research is to overcome several hurdles in 
stem cell research. Human pluripotent stem cells such as hESC and 
hiPSC suffer from apoptosis in single cell-dissociation. Because of 
pre-activated Bax at Golgi in cells, hESC and hiPSC induced rapid 
apoptosis in stress condition. We applied 30Kc6 in hiPSCs. hiPSC-
30Kc6 was expressed pluripotent stem cell markers, and had a 
potency of differentiation in three germ layers. Also, the viability of 
single cells was higher than normal hiPSCs.  
Then, we wondered that anti-apoptotic property of 30Kc6 was 
from a specific domain of 30Kc6. From the apoptosis research, BH4 
domain of Bcl2 inhibited apoptosis by binding Bax. With structural 
similarity of BH4, 30Kc6 alpha-helix (30Kc6α) was considered as 
anti-apoptotic domain. By truncation, we cloned 30Kc6α and 
observed anti-apoptotic property. Furthermore, 30Kc19-30Kc6α 
protein could penetrate cell, and showed enhanced cellular viability 
under STS or UV-irradiation condition.  
Cell-penetration and enzyme-stabilization are the properties on 
30Kc19 protein. We tried to solve the problems on reprogramming 
which are instability and low solubility of transcription factor proteins. 
Previous reprogramming methods had a risk of transgene integration 
iii 
 
to host genome. By using protein, transcription factors were 
delivered directly without any DNA-related complications. To 
express transcription factors as soluble form, 30Kc19 was 
conjugated. 30Kc19 conjugated transcription factors (Oct4, Sox2, c-
Myc, and Klf4) were expressed as a soluble protein. Purified soluble 
transcription factors were penetrated into cells, and stable up to 48 
h. Furthermore, Klf4-30Kc19 protein showed a transcriptional 
activity. 
Lastly, we generated neuronal cells using transcription factor with 
30Kc19. 30Kc19-Ascl1-NLS-R9 protein induced successfully 
mouse embryonic fibroblasts (MEFs) to protein-induced neuronal 
cells (p-iNCs). p-iNCs had neuronal morphology, and expressed 
neuronal markers (Tuj1 and MAP2). Furthermore, the expression 
levels of neuronal genes (ASCL1, BRN2, and MYT1L) were observed 
higher on day 7 and 14. 
In this research, we applied anti-apoptotic 30Kc6 and cell-
penetrating 30Kc19 protein on stem cell research. This approach will 
give a chance for developing new techniques in stem cell research.  
 
Keywords: 30K protein, 30Kc6, 30Kc19, anti-apoptosis, cell 
penetration, recombinant protein, transcription factor, stem cell, 
direct conversion 
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Chapter 1. Research background and objective 
 
30K proteins are derived from silkworm hemolymph (SH), and 
introduced previously as a substitute for fetal bovine serum [1]. SH 
increased host cell longevity [2], and inhibited apoptosis in insect 
[3-5] and human cells [6]. Components of SH were isolated to 
identify the property [7, 8]. As a result, purified 30K proteins from 
SH had an interesting role for inhibiting apoptosis in various cells. 
Among 30K protein family (30Kc6, 30Kc12, 30Kc19, 30Kc21, and 
30Kc23), 30Kc6 had anti-apoptotic property in insect and 
mammalian cells [9]. 30Kc6 inhibited apoptosis with similar effect of 
whole SH. 30Kc6 protein was expressed in Escherichia coli (E. coli) 
[10], and the recombinant protein was tested anti-apoptotic effect 
by comparing with whole SH. Due to 30Kc6 protein was expressed 
in the form of an inclusion body, further denaturation and refolding 
steps were required. Although 30Kc6 has to be reconstructed, 
recombinant 30Kc6 protein also had effect of anti-apoptosis in insect 
(Sf9) and mammalian cell (HeLa) [11]. By using 30Kc6 anti-
apoptotic property, the production rates of  antibody [12], 
recombinant interferon-β [13], and human erythropoietin (EPO) 
3 
 
[14, 15] were increased. 
The most abundant component, among 30K proteins, is 30Kc19 
protein. 30Kc19 protein was reported cell-penetrating property in 
cells, also 30Kc19 protein could penetrate in vivo [16]. When 
30Kc19 protein injected into mice, 30Kc19 protein was observed in 
various organ tissues. The mechanism for penetration was known as 
a dimerization by Cys-58 of 30Kc19 [17]. Cell-penetrating peptide 
(CPP) in 30Kc19 protein takes charge of these property. The cell-
penetrating peptide of 30Kc19 protein (Pep-c19) was identified, and 
Pep-c19 was penetrated efficiently into cells, and delivered cargo 
proteins [18]. In vivo delivery, Pep-c19 dragged GFP in various 
organ tissues. Another property of 30Kc19 is enhancement stability 
of enzyme. By adding 30Kc19 protein with enzyme solution, the 
stability of alkaline phosphatase (AP) and horse radish peroxidase 
(HRP) was enhanced [19]. Furthermore, the stability of cellular 
mitochondrial enzyme complex and sialytransferase was increased 
by adding 30Kc19 protein to solution [20]. This stabilizing property 
is considered by non-specific crowding effect. Furthermore, 30Kc19 
protein and human serum albumin nanoparticles were generated, and 
successfully delivered enzyme into cells or organs with low 
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cytotoxicity [21]. Recently, 30Kc19 N-terminal region (30Kc19α) 
was reported same or higher penetrating and stabilizing properties 
than 30Kc19 whole protein [22]. 
In this research, 30Kc6 anti-apoptotic protein and 30Kc19 cell-
penetrating protein were applied to cellular engineering. First, 30Kc6 
protein was used to cellular reprogramming to solve apoptosis 
derived from single cell-enzymatic dissociation. Then, to investigate 
the anti-apoptotic property of 30Kc6, we truncated 30Kc6 as N-
terminal alpha helix region (30Kc6α). Then, 30Kc6α was 
conjugated with 30Kc19 protein in the purpose of cell-penetrating 
and soluble expression. By using multifunctional properties, 30Kc19 
protein was also conjugated with reprogramming factors (Oct4, Sox2, 
c-Myc, and Klf4) for reprogramming. Lastly, 30Kc19-conjugated 
Ascl1 protein could induce mouse fibroblasts to neuronal cells. 
 
In summary, the objectives of this study are: 
1. Application of 30Kc6 anti-apoptotic protein on apoptosis 
derived from single cell-enzymatic dissociation in human 
induced pluripotent stem cell (hiPSC) 
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2. Investigation anti-apoptotic property of 30Kc6α, and protein 
expression of 30Kc6α with 30Kc19 cell-penetrating protein 
3. Application of 30Kc19 cell-penetrating protein on production 
of reprogramming factors 
4. Application of 30Kc19 cell-penetrating protein on direct 
conversion 
 
In the thesis, 30Kc6 and 30Kc19 proteins were applied into cell 
engineering by using their properties. Especially, 30Kc6 could 
enhance viability of hiPSC. Also, 30Kc19 could help cellular 
reprogramming by conjugating with reprogramming factors. These 

















Chapter 2. Literature review 
 
2.1 Cellular reprogramming 
Transcription factor is a protein that controls the gene regulation, 
and has the potential of being used as a drug. Since the finding of 
Yamanaka factors (Oct4, Sox2, Klf4, and c-Myc) [23, 24], research 
on cellular reprogramming has been actively carried out. This study 
offers unprecedented potential for disease research and regenerative 
medicine. Also, by generating induced pluripotent stem cells (iPSCs), 
the ethical problems from the use of embryonic stem cells (ESCs) 
can be avoided. Recent trend of cellular reprogramming is direct 
reprogramming, also known as transdifferentiation or direct 
conversion. Some transcription factors for direct conversion have 
been identified; such as MyoD for myoblasts [25], Gata4, Mef2c, and 
Tbx5 for cardiomyocytes [26], Ngn3, Pdx1, and Mafa for pancreatic 
beta cells [27], ETV2, FLI1, and ERG1 for endothelial cells [28], 
Ascl1, Brn2, and Myt1l for neurons [29], PDX-1 for insulin-
producing cells [30]. Direct conversion is in the spotlight because it 





Table 2.1 Examples for use of transcription factors in cellular reprogramming and direct conversion 
 
Transcription factors Cell type References 
Oct4, Sox2, Klf4, and c-Myc iPSCs [23,24] 
MyoD Myoblasts [25] 
Gata4, Mef2c, and Tbx5 Cardiomyocytes [26] 
Ngn3, Pdx1, and Mafa Pancreatic beta cells [27] 
ETV2, FLI1, and ERG1 Endothelial cells [28] 
Ascl1, Brn2, and Myt1l Neurons [29] 




2.2 Reprogramming methods 
2.2.1 Virus 
For reprogramming, the most conventional methods are viral 
transduction. Retrovirus generated iPSCs from various cell types for 
example mouse fibroblasts [23], human fibroblast [24, 31, 32], or 
human keratinocytes [33]. Retrovirus has 0.001-1% efficiency. 
Lentivirus is more efficient than retrovirus because it can infect both 
non-dividing and proliferating cells. The efficiency of lentivirus is 
0.1-1.1%, and with high efficiency there are some reports for 
reprogramming using lentivirus [34-36]. Also, to control expression 
of transcription factors, inducible lentivirus is used. By using 
doxycycline-inducible lentiviral system, exogenous factors can be 
expressed when transactivator exists [37, 38] However, the use of 
retrovirus and lentivirus is limited due to the risk of tumorigenicity 
by incorporating of viral vector sequences into the host genome.  
Non-integrating adenovirus or sendai virus can be alternative. 
Adenovirus transiently expressed transcription factors, and 
generated mouse and human iPSCs without genome-integration [39, 
40]. Furthermore, hepatocytes transdifferentiated into insulin 
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producing cells by adenovirus-mediated gene transfer [30]. 
However, the efficiency of adenovirus was only 0.0001-0.001%. 
Sendai virus as non-integrating virus is an RNA virus, which does 
not enter the nucleus. By using sendai virus, iPSCs were generated 
from fibroblasts [41], cord blood cells [42], and T cells [43]. 
Although the efficiency of sendai virus is relatively high (0.1-1%), 
it required about 10 passages for losing viral gene, also the cells have 
to incubate at a higher temperature for removing temperature-
sensitive virus.       
 
2.2.2 DNA 
To diminish the risk of integration, episomal plasmids, encoding  
transcription factors, were applied [44]. However, because transient 
expression is not maintained transcription factor for reprogramming, 
the reprogramming efficiency was low (0.0003-0.0006%) [34]. To 
overcome low efficiency, repeating transfection was tried. As a result, 
episomal plasmids could induced iPSCs. iPSCs by episomal plasmids 
were expressed pluripotent markers, and formed teratomas [45]. A 
nonviral minicircle plasmids had higher transfection efficiencies due 
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to lower activation of exogenous silencing mechanisms [46, 47]. Also, 
minicircle DNA vectors are free of bacterial DNA. Minicircle plasmids 
contained a cassette of transcription factors with a green fluorescent 
protein (GFP), and transfected cells were sorted by GFP [48]. There 
was a report about generation iPSCs from human adipose stromal 
cells (hASCs) by repeating transfection of minicircle DNA [49]. 
Exogenous plasmids were lost after 12 passages, and iPSCs were 
transgene-free condition. These DNA methods are advantageous in 
clinic because of the absence of genomic modification. However, the 
reprogramming efficiency is still low (-0.005%), and repeating 














Figure 2.1 Minicircle DNA system and cell transfection 
 
Parental plasmid includes reprogramming factors and GFP with 
bacterial plasmid elements. When arabionose is added, plasmid 
backbone is degraded, and minicircle DNA is remained. GFP is 
expressed in minicircle transfected cells. By FACS, GFP+ cells which 




2.2.3 mRNA and miRNA 
RNA-induced pluripotent stem cells (RiPSCs) were successfully 
generated without genomic integration [51]. Also, using mRNA can 
generate footprint-free iPSCs. The efficiency of mRNA was reported 
1.4% in human fibroblasts. From the study, RiPSCs were 
differentiated to myogenic cells. However, the methods are labor 
intensive and additional days are required for preparing mRNA. 
MicroRNA is another method for cellular reprogramming. There were 
studies of stromal cells and fibroblasts induced iPSCs using mir-
200c plus mir-302s, and mir-369s family miRNAs [52]. Similarly, 
miR-302 and miR-372 induced human fibroblasts to iPSCs [53]. 
These miRNAs suppressed multiple downstream target genes, and 
controlled cellular process such as cell cycle and epithelial-
mesenchymal transition (EMT). The cluster of the miR302/367 was 
reported for efficient method to generate iPSCs [54]. Due to the 
expression of miR302/367 activated Oct4 gene expression, 
miR302/367 iPSCs were showed similar characteristics to 
Oct4/Sox2/c-Myc/Klf4 iPSCs. The miRNA method takes shorter 




2.2.4 Cre/LoxP and PiggyBac transposon 
In the excision approach, Cre/LoxP recombination make iPSCs to 
be a factor-free condition. Cre/LoxP recombination is a more 
suitable for disease modeling. Somatic cells from Parkinson’s 
disease patients were generated iPSCs, and differentiated 
successfully into dopaminergic neurons [55]. An excisable loxP-
flanked lentiviral was also used for reprogramming [56]. The 
efficiency was reasonable (0.1`-1%), but loxP sites can retain in the 
genome.  
Another excision approach is piggyBac transposon. Transposon is 
a footprint-free method because it is able to integrate into 
chromosome TTAA sites as a mobile genetic element, then 
transposon can excise in re-expression of the transposase [57]. 
Using piggyBac vector, human mesenchymal stem cells (MSCs) were 
generated to iPSCs with 0.02% efficiency [58]. The exogenous 
factors in iPSCs were removed completely. The hurdle of use for 
piggyBac transposon is that screening for excised lines is labor-
intensive. Although the disadvantage, these excision methods are 






Figure 2.2 Transposon vector system 
For transgene delivery, gene of interest (GOI) is between the 
transposon terminal inverted repeats (Black arrows). GOI is inserted 




Protein is considered as a safer method for cellular reprogramming 
due to direct delivery of transcription factors. There were not 
genomic integration and any of DNA-related complications. There 
were studies for reprogramming using direct delivery of proteins. 
Four reprogramming proteins (Oct4, Sox2, c-Myc, and Klf4) were 
produced in HEK cells [60]. By using these proteins, human 
fibroblast induced iPSCs with 0.001% efficiency. However, the 
concentration of delivered factors were limited due to cytotoxicity of 
the whole-protein extracts. To solve this problems, proteins were 
produced from E. coli expression system [61]. Four reprogramming 
proteins were produced in large scale from E. coli, and purified. Using 
these purified proteins, OG2/Oct4-GFP reporter MEF cells were 
induced iPSC, and expressed pluripotent markers. However, unlike 
mammalian proteins, E. coli proteins were formed aggregation and 
required extra refolding steps. Although the protein method is 
suitable to regenerative medicine with high safety, the limitations are 
short half-life of unstable protein. Also, large amount pure proteins 





Table 2.2 Methods for reprogramming and the efficiency 
Methods Efficiency (%) References 
Virus Retrovirus 0.001-1 [32, 33] 
Lentivirus 0.1-1.1 [34-35, 38] 
Adenovirus 0.0001-0.001 [40] 
Sedai virus 0.1-1 [41-43] 
DNA Episomal plasmid 0.0003-0.0006 [44, 45] 
Minicircle DNA -0.005 [50] 
RNA mRNA 1.4 [51] 
miRNA -0.1 [54] 
Cre/LoxP and Piggy Bac Cre/LoxP 0.1-1 [56] 
PiggyBac 0.02 [58] 















Chapter 3. Experimental procedures 
3.1 Gene cloning 
Template genes were obtained from Silkworm hemolymph total 
RNA (Kim et al. 2001) or Addgene (Oct4 #17217, Sox2 #17218, c-
Myc #17220, Klf4 #17219, L-Myc #26022). The genes were 
amplified by reverse transcriptase polymerase chain reaction (RT-
PCR). RT-PCR products were inserted into a pET23a vector 
(Novagen, Madison, WI, USA) for protein expression, and the vector 
was designed with a T7 tag at the N-terminus for immunoassay and 
His tag at the C-terminus for purification. For viral expression, RT-
PCR products were inserted into a pMXs vector (Cell biolab, San 
Diego, CA, USA). The cloned genes were verified by GenoTech. 
(Daejeon, Korea). The restriction enzyme sites were used BamH1, 
EcoR1, and Xho1.  
 
3.2 Protein production and analysis 
   3.2.1 Protein expression and purification 
Each vector was transformed to E. coli BL21 (Novagen), and cells 
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were cultured in LB medium with 100 μg/ml ampicillin. When OD600 
reached 0.6 at 37℃, isopropyl-β-D-thiogalactopyranoside (IPTG) 
was added to a final concentration of 1 mM. For protein expression, 
the cells were further incubated at 27 or 37℃. Harvested cells were 
disrupted by ultra-sonication in a lysis buffer (20 mM Tris-HCl, 0.5 
M NaCl, 20 mM imidazole, pH 8.0) and separated by centrifugation 
(12,000 rpm). The soluble proteins in the supernatant were collected 
and loaded on a HisTrap HP column (GE Healthcare, Uppsala, 
Sweden) using FPLC (GE Healthcare). The washing buffer (20 mM 
Tris-HCl, 0.5 M NaCl, 50 mM imidazole, pH 8.0) was placed into the 
column to remove unbound proteins. Finally, target proteins were 
eluted with the elution buffer (20 mM Tris-HCl, 0.5 M NaCl, 350 mM 
Imidazole, pH 8.0) and dialyzed against Tris-HCl (pH 8.0). 
 
3.2.2 Quantitative analysis using BSA standard solution 
For quantitative analysis of purified protein, the protein samples 
were analyzed by comparing with BSA standard solution. The 
proteins were mixed with 5 x sample buffer (0.25 M Tris-HCl, 0.5 
M DTT, 10% SDS, 50% Glycerol, and 0.5% Bromphenol blue, pH 6.8), 
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then boiled for 5 min. The prepared protein samples and BSA 
standard solution were separated through 10% sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), and 
stained by Coomassie Brilliant Blue (Thermofisher scientific, 
Waltham, MA, USA). After staining, the band size was calculated 
using Image J software.  For high purity protein, Micro BCATM 
Protein Assay Kit (Thermofisher scientitific) was used to analyze 
quantity of total protein. 
 
3.2.3 Western blot analysis for in vitro stability assay 
 Purified soluble proteins were incubated in 37℃ for 24 or 48 h. 
After incubation, the samples were separated through 7.5% (protein 
size 70-120 kDa), 10% (30-70 kDa), and 12% (15-30 kDa) SDS-
PAGE, and transferred onto a polyvinylidene difluoride (PVDF) 
membrane (GE Healthcare). The membranes were blocked with 5 % 
skim milk in TBS with 0.1% tween 20. Anti-T7 primary antibody 
(Abcam, Cambridge, UK) and anti-rabbit horseradish peroxidase 
(HRP)-conjugated secondary antibody (Millipore, Bedford, MA, USA) 
were used for immunoblot analysis. Luminata Forte Western HRP 
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Substrate (Millipore) was used as substrate of HRP. The band was 
visualized by G:BOX Chemi XL system (Syngene, Cambridge, UK), 
and the band intensities were quantified using Image J software. 
 
3.3 Cell culture 
3.3.1 Primary cell isolation and culture 
For primary mouse embryonic fibroblast (MEF), 13.5 days 
pregnant mice (the C57/BL6 strain) were prepared. Embryos from 
the mice were harvested, then separated fibroblasts from embryos. 
The separated fibroblasts were washed twice with PBS, then 
dissociated as single cells using 0.25% trypsin-EDTA (Gibco, 
Carlsbad, CA, USA). After removal larger embryo fragments, the 
cells were incubated in 37℃ with MEF culture medium, Dulbecco’s 
modified eagle medium (DMEM) with 10% fetal bovine serum (FBS, 
Gibco) and 1% penicillin streptomycin (PS, Thermofisher scientitific). 
Every 3-5 days later, the cells were transferred into new dish using 




3.3.2 Embryonic stem cell culture and embryoid body 
formation 
Wild type of human embryonic stem cell (hESC), SNUhES31, and 
mouse embryonic stem cell (mESC) were offered from Institute of 
Reproductive Medicine and Population, Medical Research Center, 
Seoul National University, Seoul, Korea). Embryonic stem cells were 
cultured on feeder layers of mitomycin-C (Sigma-aldrich, St. Louis, 
MO, USA)-treated 2 x 105 STO cells per 35 mm gelatin-coated dish 
(ATCC® CRL-1503, Manassas, VA, USA) in DMEM/nutrient 
mixture F-12 ham (Thermofisher scientific) with 20% knockout 
serum replacement (Thermofisher scientific), 0.1 mM of 2-
mercaptoethanol (Sigma-aldrich), 1% PS, 1% MEM non-essential 
amino acids solution (Thermofisher scientific), and 5 ng/ml of 
recombinant human FGF-2/FGF-basic (Biovision, Milpitas, CA, 
USA). Cells were passaged onto fresh STO cells every week by 
mechanical transfer. For feeder free, cells were cultured with 
essential 8 medium (Thermofisher scientific) on the geltrex® 
(Thermofisher scientific)-coated dish.  
To form embryoid body (EB), hESCs were detached using 
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collagenase type Ⅳ (Gibco) 4 days after mechanical transfer. The 
detached colonies were suspended for 7 days on Petri dish 
(Thermofisher scientific). The medium was changed every 2-3 days 
in DMEM)/nutrient mixture F-12 ham (Thermofisher scientific) with 
10% FBS (Gibco) and 1% PS (Thermofisher scientific). The EBs 
were harvested and the expression levels of pluripotency (OCT4, 
NANOG), ectoderm (PAX6, ZIC1), endoderm (SOX17, GATA4), and 
mesoderm (GATA2, TAL1) markers were analyzed by real-time 
quantitative PCR (RT-qPCR) on a StemOnePlus Real-Time PCR 
(Thermofisher scientific). The comparative CT method (∆∆CT) was 
calculated by normalization of GAPDH. The primer sequences are 
listed in Table 3.6.2.  
 
3.4 Generation of induced pluripotent stem cell (iPSC) 
3.4.1 Retrovirus production 
Gp2-293 packaging cells (Clontech laboratories, Mountain view, 
CA, USA) were plated at 1 x 106 cells per 100 mm dish and incubated 
overnight. Cells were transfected with 30Kc6 and pVSV-G using 
Lipofectamine® 3000 (Invitrogen, Carlsbad, CA, USA) according to 
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the manufacturer’s instructions. After 48 h incubation, the virus-
containing medium was collected and filtered through a 0.45 μm 
membrane filter (Pall corporation, Washington, NY, USA). The virus 
was precipitated using Retro-ConcentinTM (System biosciences, 
Palo Alto, CA, USA). The precipitated virus was suspended using 
DMEM and stored at -70℃ for further use. DsRed containing virus 
was made for analysis of viral transduction efficiency. 
 
3.4.2 Viral transduction and iPSC culture 
Human dermal fibroblasts (ATCC® PCS-201-010) and isolated 
MEFs were seeded at 1 x 105 cells per 35 mm dish and incubated 
overnight. Oct4, Sox2, c-Myc, and Klf4 virus-containing DMEM 
medium was added to cells supplemented with 8 μg/ml of polybrene, 
and cells were incubated in 37℃ for more than 18 h. On the next day, 
the cells were incubated in new DMEM media and cultured for 3-5 
days more. When colonies were appeared, the colonies were picked 
up using pasteur pipettes (Sigma-aldrich). The iPSC colonies were 







Figure 3.1 Procedure for generation of human iPSC 
A. Retrovirus production. B. Viral transduction and iPSC culture. 
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3.5 Generation of protein-induced neuronal cell (p-iNC) 
On day 0, isolated mouse embryonic cells (MEFs) and glial cells 
(astrocytes, obtained from Center for Medical Innovation, Seoul 
National University Hospital) were seeded and co-cultured in DMEM 
supplemented with 10% FBS and 1% PS. For the next 2 days, medium 
was exchanged with fresh media containing 30 μg/ml of 
reprogramming protein with 2 mM VPA (Thermo Fisher Scientific 
Inc.). On day 3, the medium was replaced with N3 media (DMEM/F12, 
N2 supplement, B27, 12.5 mg insulin, and PS) containing 30 μg/ml 
of reprogramming protein. On the next day, medium was replaced 
reprogramming protein-free N3 media. Proteins were treated every 
3 days until day 14. 
 
3.6 Cell analysis 
3.6.1 RNA isolation and cDNA synthesis 
 hESCs and iPSCs were separated from feeder cells using 
collagenase type Ⅳ (Gibco, Carlsbad, CA, USA) and disrupted using 
1 ml of TRI Reagent® (Sigma) per 5 x 106 cells. After addition of 
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200 μl of chloroform, cells centrifuged at 12,000 x g for 15 min at 
4℃. An upper aqueous phase was collected and mixed isopropyl 
alcohol. After centrifugation at 12,000 x g for 10 min, the supernatant 
was removed and the pellet was washed with 75% ethanol. The 
synthesis of cDNA was using M-MLV cDNA synthesis kit 
(Enzynomics) according to manufacturer’s instructions.  
 
 3.6.2 RT-PCR and quantitative RT-PCR 
To amplify DNA, reverse transcription polymerase chain reaction 
(RT-PCR) was used. Template DNA and primers were added with 
AccuPower® PCR premix (Bioneer). For quantitative RT-PCR, 500 
ng RNA was reverse transcribed into cDNA using the first Strand 
cDNA Synthesis kit (Promega) with SuperScriptTM II reverse 
transcriptase. Template cDNA was amplified using SYBR Master Mix, 
and real-time quantitative PCR (RT-qPCR) was carried out on the 
Lightcycler® 480 System (Roche Applied Science). The comparative 
CT method (∆∆CT) was calculated by normalization of GAPDH. The 






Table 3.6.2 Primers for real-time quantitative PCR 
 









































  For immunocytochemistry of cells, the cells were fixed using 4% 
paraformaldehyde (Sigma-aldrich) for 15 min, then permeabilized 
using 0.05% tween-20 (Amresco, Cleveland, OH, USA) for 2 h. 
Anti-Tra-1-60 (Abcam, Cambridge, UK) and anti-Oct4 (Santa 
Cruz Biotechnology, Dalls, TX, USA) were used as primary antibody 
(1:100). Anti-mouse Alexa 488-conjugated secondary antibody 
(1:250) was used for Tra-1-60, and Anti-rabbit Alexa 594-
conjugated secondary antibody (1:250) was used for Oct4. Hoechst 
33342 (Life Technologies, Gaithersburg, MD, USA) was stained on 
nucleus. The images were obtained by confocal fluorescence 
microscope (Olympus, Lake Success, NY, USA).   
 
  3.6.4 Live cell analysis 
For live cell imaging, recombinant proteins were labeled with an 
Alexa Fluor® 488 protein labeling kit (Invitrogen). One M Solution 
of sodium bicarbonate was added to 1 ml deionized water. Then, 1 
mg of target protein was mixed with the solution, and washed to 
remove unbound Alexa Fluor®. HDF cells were treated with labeled 
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proteins. Hoechst 33342 (Life Technologies, Gaithersburg, MD) was 
stained on nucleus and observed using confocal fluorescence 
microscope (Olympus). 
 
3.6.5 Cell viability assay 
  To assess the toxicity of protein, HDF cells were treated with 
proteins in 96-well plate. Proteins were added into cells for 12 or 24 
h. After treatment, cells were washed three times with PBS and 
treated with MTT solution for 4 h then solubilized for 12 h at 37℃. 
Absorbance at 420 nm was measured for the determination of cell 
viability. For use Cell Counting Kit-8 (Dojindo Laboratories, 
Kumanoto, Japan), the cells were incubated for 2 h with CCK-8 
solution, and the absorbance at 450 nm was measured using a 
spectrophotometer. 
 
  3.6.6 Luciferase assay 
 pGL3-Klf4 reporter plasmid and pRL-SV40 (Addgene plasmid # 
27163) were delivered into HEK293 cells using Lipofectamine® 
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3000 reagent (Invitrogen) according to the manufacturer ’ s 
instructions. One day after the transfection, cells were treated with 
proteins. A Dual-Glo® luciferase assay system (Promega, Madison, 
WI, USA) was used for measurement of luciferase. On a 96-well 
plate (Nunc Lab-Tek, Thermo Scientific, Rockford, IL, USA), the 
cells were treated with proteins for 4 h and then washed with DMEM. 
Twenty microliters of a lysis reagent were added in 20 μl of DMEM 
medium. After 10 min of incubation, the firefly luminescence was 
measured using Luminometer (Thermo Scientific). Then 20 μl of 
stop reagent was added before measurement. The ratio of 
Firefly/Renilla luminescence was calculated, and each well was 
normalized from a control well. 
 
3.6.7 Apoptosis induction and FACS analysis 
 For induction of apoptosis, hiPSC-30Kc6 and hiPSC were 
incubated with 0.5 μM of Staurosporine (Sigma-aldrich) and 20 
mJ/cm2. After additional 24 h incubation at 37℃, the cells were 
analyzed using flow cytometry. Before analysis, the cells were 
treated with AccutaseTM (Stem cell technologies, Vancouver, BC, 
34 
 
Canada) for single-cell dissociation after PBS washing twice. For 
flow cytometry analysis, the dissociated cells were washed and 
labeled with FITC Annexin V using FITC Annexin V Apoptosis 
Detection Kit (BD biosciences, San Jose, CA, USA). Cells (1x106) 
were collected and resuspended in 1 ml of 1x binding buffer. 100 μ
l (1x105 cells) of cell suspension was incubated with 5 μl of FITC 
Annexin V and 5 μl of propodium iodide (PI) for 15 min in dark room. 
Then 400 μl of 1x binding buffer was added. FACS AriaⅡ (BD 
biosciences) was used for analysis. The statistical analysis has been 
performed using SigmaPlot software. The p values were obtained 
from t-test in the software (*p < 0.05, **p < 0.01, ***p < 0.001). 
 
3.6.8 Single cell-dissociation and alkaline phosphatase 
staining 
The colonies were dissociated to single cells using AccutaseTM, 
and 5 x 104 single cells were seeded on feeder. On day 7 of culture, 
the colonies were characterized by alkaline phosphatase staining. 
The AP positive colonies were counted using image J software. The 
statistical analysis has been performed using SigmaPlot software. 
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The p values were obtained from t-test in the software (*p < 0.05, 
**p < 0.01, ***p < 0.001). For alkaline phosphatase staining, the cells 
were washed twice with PBS after fixation, then stained using 
Leukocyte Alkaline Phosphatase Kit (Sigma-aldrich) according to 
the manufacturer’s instructions. The stained cells were observed 
by optical microscope (Olympus). 
 
3.6.9 Electrophysiological recording 
The cells were observed on a submerged recording chamber 
(Warner instrument, Hadmen, CT, USA). A Multiclamp 700B 
amplifier (Molecular Devices, Foster City, CA, USA), Clampex 10.3 
of the pClamp software package (Molecular Devices) were used for 
electrophysiological recordings. All recordings were patched using 
internal solution containing 115 mM potassium gluconate, 10 mM KCl, 
10 mM HEPES, 10 mM EGTA, 5 mM Mg2+ -ATP and 0.5 mM 
2Na+-GTP (pH7.3 and 280-285 mOsm). The extracellular solution 
contained 124 mM NaCl, 3 mM KCl, 1.3 mM MgSO4, 1.25 mM 
NaH2PO4, 26 mM NaHCO3, 10 mM glucose and 2.4 mM CaCl2·2H2O 
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Chapter 4. Anti-apoptotic effect of 30Kc6 gene on 
human induced pluripotent stem cell 
 
4.1 Introduction 
Since the finding of human induced pluripotent stem cell (hiPSC), 
several studies have been made on hiPSC. Attention has focused on 
the use of hiPSC in regenerative medicine by using their pluripotency. 
Also, hiPSC could avoid ethical issues that may arise in human 
embryonic stem cell. However, the culture of hiPSC is time 
consuming and labor intensive [62, 63]. Due to easily apoptosis in 
single cells, hiPSC is required to transfer as a form of colony (Figure 
4.1).  
There are several studies about genetic engineering of pluripotent 
stem cells to inhibit apoptosis. Penninger’s group reported that 
inactivation of AIF renders had effect on inhibition of cell death in 
serum deprivation [64]. The suppression of p53 by short-interfering 
RNA (siRNA) enhanced the reprogramming efficiency by preventing 
apoptosis during culture [65]. Also, there was a report that over 
expression of Oct4 helps undifferentiated hESC survival under stress 
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[66]. By using nuclease, transcription activator-like effector 
nucleases (TALENs) was engineered genetically in hESC and hiPSC 
[67]. 
In this study, we applied 30Kc6 anti-apoptotic gene to hiPSCs. We 
hypothesized that 30Kc6 could inhibit apoptosis in hiPSC as like 



















Figure 4.1 Human pluripotent stem cell (hPSC) colony in 
culture, and mechanical transfer 
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4.2 Retroviral transduction and expression of hESC-specific 
genes in hiPSC-30Kc6 
 
 OCT4, SOX2, c-MYC, KLF4, 30Kc6, or DsRed retrovirus were 
produced respectively. By using DsRed, a transduction efficiency of 
retrovirus on HDF cells was tested, and many of DsRed-fluorescent 
cells were observed in virus-treated HDF cells (Figure 4.2 A). Like 
fluorescent image, the results of flow cytometry were showed that 
the transduction efficiency was 73.6%. With high transduction 
efficiency, viral OCT4, SOX2, c-MYC, and KLF4 were treated on 
HDF cells for reprogramming. At the same time, we also added viral 
30Kc6 in order to generate hiPSC-30Kc6. Therefore, hiPSC and 
hiPSC-30Kc6 were generated from HDF cells. To observe the 
expression of human embryonic stem cell (hESC)-specific genes in 
hiPSC-30Kc6, the cells were lysed, and cDNA was synthesized from 
mRNA. From Figure 4.2 B, RT-PCR results showed that hiPSC-
30Kc6 expressed 30Kc6 gene as well as hESC-specific genes, 
including OCT4, SOX2, c-MYC, KLF4, and NANOG. Thus, we 
established hiPSC line containing with 30Kc6, and it expressed 
hESC-specific genes as like hiPSC and hESC. 
hiPSC-30Kc6 has been cultured stably for more than 15 passages 
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on the feeder cells, and we observed the tightly compact colonies. 
The morphology of hiPSC-30Kc6 was round, and the colonies had 
clearly defined edges (Figure 4.2 C). Due to essential process to 
check whether pluripotent properties were existing or not after 
exogenous gene insertion, pluripotency markers (Tra-1-60 and 
Oct4) were analyzed by immunocytochemistry. From fluorescence 
image, hiPSC-30Kc6 expressed well Tra-1-60 and Oct4 as like 
hiPSC, and hESC. Although the nuclei were stained in all cells 
including feeder cells, Tra-1-60 and Oct4 were stained only in 
pluripotent stem cells. Moreover, alkaline phosphatase (AP) activity, 
an undifferentiated marker, was observed by staining (Figure 4.2 D). 
We observed that the colonies of hiPSC-30Kc6 were stained with 
strong AP activity. From these results, we concluded that hiPSC-









Figure 4.2 Retroviral transduction on HDF cells and expression 
of pluripotent markers  
 
A. FACS analysis for the efficiency of viral transduction (DsRed). B. 
RT-PCR analysis of endogenous hESC-specific genes and 30Kc6 
gene in hiPSC-30Kc6. C. Immunocytochemistry of pluripotency 
markers, Tra-1-60 (Green) and Oct4 (Red). Nuclei were stained by 
Hoechst 33342 (Blue). Scale bar, 200 μm. D. Alkaline phosphatase 
staining. Scale bar, 500 μm. 
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4.3 In vitro differentiation of hiPSC-30Kc6 
 
To check differentiation potency of hiPSC-30Kc6, we generated 
embryoid body (EB). On day 7 after formation, the size of EB was 
about 300 μm diameter (Figure 4.3 A). Then, EBs were collected 
and analyzed specific markers by RT-qPCR. On figure 4.3 B, hiPSC-
30Kc6 was showed that pluripotency markers (Oct4, Nanog) were 
decreased, although the differentiated markers, ectoderm (PAX6, 
ZIC1), endoderm (SOX17, GATA4), and mesoderm (GATA2, TAL1), 
were increased. The values from RT-qPCR were normalized to 
GAPDH. It was similar results with hESC and hiPSC. This data 
indicated that hiPSC-30Kc6 had potency of differentiation in three 
germ layer. Therefore, we had no doubt that the insertion of 30Kc6 






Figure 4.3 In vitro differentiation of iPSC-30Kc6 
 
A. Embryoid body (EB) formation at day 7. Scale bar, 500 μm. B. 
Real-time quantitative PCR analysis of differentiated EB. 
Pluripotency (OCT4, NANOG), ectoderm (PAX6, ZIC1), endoderm 
(SOX17, GATA4), mesoderm (GATA2, TAL1) markers. Error bars 
represent standard deviation (n=3).  
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4.4 Anti-apoptosis effect on hiPSC-30Kc6 
In previous study, we observed that 30Kc6 inhibit apoptosis in 
insect and mammalian cells [9, 12, 68]. 30Kc6 prevented the binding 
of Bax to mitochondria, therefore cytochrome c was not released 
[12]. We hypothesized that 30Kc6 could inhibited apoptosis on 
hiPSCs. To induce apoptosis, we treated 0.5 μM of Staurosporine 
(STS) to cells. The apoptotic cells were detected by Annexin V, then 
analyzed by flow cytometry (Figure 4.4). Two colonies of hiPSC-
30Kc6 or hiPSCs were selected randomly, and analyzed. After 4 h of 
STS treatment, the percentage of Annexin V positive cells in hiPSC-
30Kc6 were relatively lower than hiPSCs (Figure 4.4 A). hiPSC-
30Kc6 #1 and hiPSC #1 which were the lowest apoptotic cells, were 
selected, and further experiments were processed. After 24 h 
treatment of STS, there were considerable difference between 
hiPSC-30Kc6 and hiPSC (Figure 4.4 B). hiPSCs showed 14.2% 
apoptosis. It was 1.43 times higher than the percentage of apoptosis 
in STS treated hiPSC-30Kc6, which was 9.9%. Another apoptosis 
was induced by UV-irradiation (Figure 4.4 C). Because UV-
irradiation induced both intrinsic and extrinsic apoptosis, apoptotic 
cells were analyzed by caspase-3 activity. Relative caspase-3 
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activity of hiPSC was 1.42 times higher than that of hiPSC-30Kc6. 
From the result, we confirmed that 30Kc6 anti-apoptotic property is 










Figure 4.4 Anti-apoptotic property in hiPSC-30Kc6 
 
A. FACS analysis for Annexin V positive apoptotic cells after 4 h of 
STS treatment. B. 24 h of STS treatment. C. Casepase-3 activity 
assay after 20 mJ/cm2 UV-irradiation. *p < 0.05, **p < 0.01, ***p < 






4.5 Single cell-dissociated cell viability 
Due to single cells of hiPSC are weak to apoptosis, the subculture 
of colonies is required. We have tried to apply 30Kc6 on single cell-
dissociation. Before single cell-dissociation, hiPSC-30Kc6 and 
hiPSC were cultured on feeder free condition. Cells were dissociated 
by AccutaseTM, then 5 x 104 cells were seeded on the feeder (Figure 
4.5 A). On day 7 after seeding, the most colonies were grown up 
about 200 μm diameter. AP staining was performed, and AP positive 
colonies were analyzed by image J software (Figure 4.5 B). With 
identification of the size (fixel) and circularity of colonies, non-
specific stain or the colonies which were derived from non-single 
cells were excluded for counting. Figure 4.5 C showed that the 
number of AP positive colonies in hiPSC-30Kc6 was on the average 
approximately 21, and it is 3 times higher than the number of AP 
positive colonies in hiPSC (approximately 7). This results indicated 








Figure 4.5 Cell viability on single cell-enzymatic dissociation 
 
A. Procedure of cell-dissociation using AccutaseTM. Feeder free 
culture of hiPSC-30Kc6 and hiPSC at day 0. Single cell-dissociation 
and 5 x 104 cells were seeded on feeder at day 1. At day 7 alkaline 
phosphatase (AP) staining was performed. 
B. AP staining dishes. C. The number of AP+ colonies counting by 







  To overcome the problems for easily induced apoptosis in hiPSCs, 
we introduced 30Kc6 anti-apoptotic gene in hiPSCs. First, hiPSC 
was transformed by expressing 30Kc6 protein. After several 
passaging, we confirmed the hiPSC-30Kc6 stable cell expressed 
pluripotency markers (Oct4, Tra-1-60, and alkaline phosphate). 
When the cells were induced apoptosis by Staurosporine, hiPSC-
30Kc6 cell was showed the 1.4 times less Annexin V expression 
comparing with normal hESC or hiPSC. Moreover, the viability of 
enzymatic single cell dissociation was 3 times increased in hiPSC-
30Kc6 by comparing with normal hiPSC. It means that the 
introduction of 30Kc6 seems to affect hiPSC by inhibiting of 
apoptosis. Therefore, the technology using 30Kc6 is anticipate to be 
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Chapter 5. Anti-apoptotic role of 30Kc6 alpha helix 
domain and its application by conjugating with 
30Kc19 protein  
 
5.1 Introduction 
Apoptosis is known as programmed cell death, which is related to 
many diseases such as Alzheimer’s disease and Parkinson’s 
disease [69, 70]. Study of the inhibition of apoptosis is a required 
field not only for the treatment of these diseases, but also for the 
production of valuable products in biotechnological industry.  
Previously in our study, 30Kc6 from Silkworm hemolymph has 
shown anti-apoptotic effect in preventing Bax translocation [12]. But 
the effect was not consistent and the mechanism was not clear. In 
this study, for more understanding of 30Kc6 anti-apoptosis property. 
30Kc6 was truncated into N-terminal all-alpha (30Kc6α) and C-
terminal all-beta (30Kc6β) domains by SWISS-MODEL program-
based sequences. Anti-apoptotic Bcl2-family proteins such as Bcl-
2, Bcl-XL, and Mcl-1 have a general structure that consists of a α-
helix [71]. BHRF1, Epstein-Barr virus-encoded protein, was 
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reported anti-apoptotic property [72].  The interaction of BHRF1 
with Bim BH3 domain inhibit the activity of pro-apoptotic Bim protein 
(Figure 5.1 A). We hypothesized that 30Kc6α could have potential 
to interact with pro-apoptotic proteins with structural basis (Figure 
5.1 B). Thus, we truncated 30Kc6α from 30Kc6, and tested the 
anti-apoptotic property. Then, to express protein, 30Kc6α was 
conjugated with 30Kc19 cell-penetrating protein. 30Kc19-30Kc6α 
recombinant protein had cell-penetrating and anti-apoptotic 
properties. This recombinant protein is anticipated in use to clinic for 








    
 
Figure 5.1 Apoptosis inhibition by structural basis 
 
A. The interaction of BHRF1 protein with Bim BH3 [72]. B. The 
expected interaction of 30Kc6 or 30Kc6α with Bim BH3.  
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5.2 Cloning of 30Kc6α and gene expression in mammalian cells 
 
30Kc6 protein had two distinct regions; N-terminal all-alpha 
(30Kc6α) and C-terminal all-beta (30Kc6β) domains. By SWISS-
MODEL program, 30Kc6 was truncated two separate proteins 
(Figure 5.2 A). 30Kc6α included amino acids 1-88, and 30Kc6β 
was amino acids 89-237 of 30Kc6 (Figure 5.2 B). With structural 
basis of 30Kc6α, we tested 30Kc6α to observe anti-apoptosis by 
comparing with 30Kc6. Fist, 30Kc6α were cloned in pcDNA3.1 
vector. When the cells were transfected to 30Kc6α, the proteins 
were expressed in cells (Figure 5.2 C). Therefore, we observed that 








Figure 5.2 The structure of 30Kc6 and protein expression 
 
A. 30Kc6 protein was truncated into N-terminal alpha-helix 
(30Kc6α), and C-terminal beta-sheet (30Kc6β) regions. B. Amino 
acid sequences of 30Kc6α. C. Gene expression of 30Kc6 and 
30Kc6α in cells. 
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5.3 Anti-apoptosis property of 30Kc6α 
  To analyze apoptotic property of 30Kc6α, cells were transfected 
with 30Kc6 or 30Kc6α. One μM of STS was treated to cells for 5 
h, then the cells were further incubation for 24 h with fresh media. 
From FACS analysis, although the percentage of apoptotic cells in 
control was 77.85, there were shown 53.29% in 30Kc6-transfected 
cells, and 44.52% in 30Kc6α-transfected cells, n=3 (Figure 5.3 A). 
It was relatively low percentage in early apoptotic cells; the apoptotic 
cells in control were 39.73%, and 30Kc6- or 30Kc6α-transfected 
cells were 17.74% or 11.78%. Interestingly, in late apoptotic cells, 
30Kc6α-transfected cells were observed the lower apoptotic 
percentage than 30Kc6-transfected cells (Figure 5.3 B). This 
results indicate that 30Kc6α had similar or higher effect on anti-
apoptosis comparing with 30Kc6. However, we did not observe anti-
apoptotic effect on primary cell, due to the low transfection efficiency. 
To solve low transfection efficiency of some cells, we tried to 









Figure 5.3 Anti-apoptotic property of 30Kc6α 
 
A. Analysis of apoptotic cells by FACS. B. Early and late apoptosis 
shown as histograms. *p < 0.05, ***p < 0.001 compared with the 










Figure 5.4 Expression and purification of 30Kc19-30Kc6α 
 
A. The structure of 30Kc19-30Kc6α. B. Expression of recombinant 
30Kc19-30Kc6α protein. C. Coomassie blue staining of purified 





5.4 Expression and purification of 30Kc19-30Kc6α protein  
 To enter the cells, 30Kc6 was conjugated genetically with 
30Kc19 cell-penetrating protein (Figure 5.4 A). 30Kc19 cloned 
vector was gained our previous study [15]. 30Kc19 has cell-
penetrating and neighbor proteins-stabilizing properties [20, 73]. 
30Kc6α was expressed aggregation form, inclusion body, from E. 
coli. However, when 30Kc19 was conjugated, 30Kc6α was 
expressed as a soluble form (Figure 5.4 B). Thus, 30Kc19-30Kc6α 
protein was expressed, and purified by FPLC. Purified soluble 
30Kc19-30Kc6α proteins were separated by SDS-PAGE, and 
analyzed by Coomassie blue staining (Figure 5.4 C) and Western blot 
(Figure 5.4 D). Thus, recombinant 30Kc19-30Kc6α protein was 
expressed as soluble and the protein band was observed in proper 
size, about 43 kDa.     
 
5.5 Cytotoxicity and cell penetration of 30Kc19-30Kc6α 
protein 
Cytotoxicity test was performed by CCK-8 assay. 30Kc19-
30Kc6α proteins were added 10, 20, 30, and 40 μM in the cell 
medium. After 24 h incubation, HeLa cells were analyzed. Although 
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10 and 20 μM of proteins had not relatively decrease in cell viability, 
30 and 40 μM of proteins showed about 85% cell viability (Figure 
5.5 A). Thus, for further use, the concentration of protein was 
considered lower than 30 μM.   
For observation of cellular penetration for recombinant proteins, we 
analyzed cells by immunocytochemistry. When the cells were 
incubated with 0.25 μM (10 μg/ml) of 30Kc19-30Kc6α for 24 h, 
the proteins were observed in cells. However, the same 
concentration of 30Kc6α protein was not entered the cells (Figure 
5.5 B). Then, we checked whether 30Kc19-30Kc6α proteins are in 
cytosol using confocal microscopy. On figure 5.5 C, 10 μM of 
30Kc19-30Kc6α protein was observed in cytosol. Thus, 30Kc19 
protein could drag 30Kc6α into cells. 
 
5.6 Anti-apoptotic property of 30Kc19-30Kc6α protein 
Anti-apoptotic effect of 30Kc19-30Kc6αwas tested. The day 
before apoptosis induction, 10 or 40 μM of 30Kc19-30Kc6α 
proteins were added in cells for 24 h. To induce apoptosis, the cells 
were incubated with 1 μM STS for 5 h. Apoptotic cells were stained 
by Annexin V-FITC, and analyzed by FACS (Figure 5.6 A). When 
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10 or 40 μM of 30Kc19-30Kc6α protein was added, the 
percentage in early apoptotic cell was 11.75 or 11.48. It was 
decrease about 25.7 or 26% comparing with control. Interestingly, in 
late apoptosis, cells with 40 μM of 30Kc19-30Kc6α protein were 
20.5% lower than cell with none (control), also 11.5% lower than 
cells with 10 μM of protein (Figure 5.6 B). Although cytotoxicity for 
40 μM of protein was observed (Figure 5.5 A), total viability of cells 
with 40 μM of protein was increased comparing with that with 10 
μM of protein. the results indicate that 30Kc19-30Kc6α protein 
had anti-apoptotic properties, and the effect on anti-apoptosis was 












Figure 5.5 Cytotoxicity and penetration of 30Kc19-30Kc6α  
 
A. Cytotoxicity analysis by CCK-8 assay. The cells were incubated 
with proteins for 24 h. Error bars represent standard deviation. (n = 
3) B. 2.5 μM 30Kc19-30Kc6α protein was observed in cells. C. 









Figure 5.6 Anti-apoptotic property of 30Kc19-30Kc6α protein  
 
A. Analysis of apoptotic cells by FACS. B. Early and late apoptosis 
shown as histograms. **p < 0.01, ***p < 0.001 compared with the 





Inhibition of apoptosis plays an important role for a treatment of 
many diseases such as Parkinson’s and Alzheimer’s disease. In 
our previous research, 30Kc6 proteins derived from silkworm 
hemolymph have been revealed as anti-apoptosis proteins in 
mammalian cells. 30Kc6 proteins are distinct two regions; N-
terminal all-alpha region and C-terminal all-beta region. We 
considered that alpha-helix regions of 30Kc6 proteins are a major 
part to take an anti-apoptotic property.  
In this study, we cloned 30Kc6 alpha (30Kc6α) to a mammalian 
expression vector, and the vector was transfected to cells. Then, 
gene transfected cells were induced apoptosis using Staurosporine 
(STS). From the analysis of Annexin V-FITC stained cells, the 
percentage of apoptotic cells in 30Kc6α was lower than that in 
30Kc6 or control.  
Furthermore, when 30Kc6α was expressed as proteins with 
30Kc19, recombinant 30Kc19-30Kc6α protein could express as 
soluble, and penetrate into cells. Lastly, 30Kc19-30Kc6α protein 
showed anti-apoptotic property. In this study, we investigated that 
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30Kc6α plays role in anti-apoptosis which whole 30Kc6 has. 
Furthermore, 30Kc19-30Kc6α protein had anti-apoptotic property 
by penetrating into cells. Thus, we anticipated 30Kc6α to be used 
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Chapter 6. Soluble expression and stability 




A transcription factor is known as a regulator that localizes into the 
nucleus and controls gene expression by binding to specific DNA 
sequences [74]. Since the generation of induced pluripotent stem 
cells (iPSCs) using four defined transcription factors (Oct4, Sox2, 
c-Myc, and Klf4), many have taken an interest because transcription 
factors have clinical significance as a therapeutic gene modulator [23, 
24]. However, a virus-based approach may cause tumorigenicity due 
to integration into the host cell genome [75]. As a solution, there 
have been many trials to evade viral transduction by using non 
integrating plasmids [76]. PiggyBac transposons [77]. and small-
molecule compounds [78]. Although plasmids and transposons can 
reduce the risks, they still have potency for genomic integration. 
Besides, molecule compounds were able to reprogram mouse cells 
but were insufficient in reprograming human cells. Thus, a protein-
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based approach is a practical method for clinical use that can limit 
safety risks and has many advantages [60].  
There were many trials to express transcription factors as 
recombinant proteins for the exploration of their mechanisms and the 
application as clinical drugs [79]. Escherichia coli (E. coli) has been 
used commonly for the production of recombinant proteins due to its 
high productivity, low production cost, and ease of product isolation 
[80]. However, there are some technical bottlenecks in the 
production of transcription factor from E. coli. For instance, the 
recombinant proteins are expressed as aggregate forms in many 
cases. As a result, it requires additional solubilization and refolding 
steps which increases production cost and decreases yield [81]. In 
addition, there is the risk that the protein may lose the original 
bioactivity after the refolding process [82, 83]. Methods to increase 
solubility have been reported by optimizing E. coli culture conditions 
[84]or through the use of a buffer system [85].  
In our previous study, 30Kc19 protein derived from Bombyx mori, 
delivered protein cargos into cells [16] by a dimerization mechanism 
[17] and enhanced enzyme stability [19, 20, 73]. Here, we have used 
30Kc19 cell-penetrating protein as a novel fusion partner of 
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transcription factors which can be used in protein-based iPSC 
generation. We anticipate that a 30Kc19 protein could deliver a 
transcription factor into cells and also solve problems that normally 
arise in the production of transcription factors, such as low soluble 
expression and protein instability. Thus, we propose that the 
multifunctional properties of 30Kc19 protein can be applied to 
general transcription factors and overcome several hurdles when 






Figure 6.1 A schematic illustration of gene regulation by transcription factor-conjugated 30Kc19 protein 
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6.2 Soluble expression and purification of transcription factors 
First of all, the effect of 30Kc19 protein conjugation to 
transcription factors on soluble expression was determined (Figure 
6.2). Transcription factors were cloned in the pET23a vector for 
recombinant protein expression in E. coli. Each factor was comprised 
with a T7 tag at the N-terminus for immunoassay and a His tag at 
the C-terminus for purification using affinity chromatography 
(Figure 6.2 A). For the delivery of protein into cells, each factor was 
fused with nine-arginine (R9) or 30Kc19. Transcription factor alone 
or with 30Kc19 was expressed in E. coli, and the lysates were 
separated into soluble and insoluble fractions. Total lysate and 
soluble fraction were then analyzed by SDS-PAGE and Western blot. 
In previous studies, most transcription factors were demonstrated to 
have poor solubility and require a solubilization process [40, 86, 87]. 
When Oct4 alone was expressed, it was expressed mainly as an 
inclusion body, and the level of soluble form was extremely low 
(Figure 6.2 B). Interestingly, a considerable amount of Oct4 
conjugated with 30Kc19 protein was expressed in soluble fraction, 
meaning that 30Kc19 protein enhanced soluble expression. For Sox2 
and Klf4, we observed that some of those transcription factors were 
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expressed as soluble proteins in our expression system as shown in 
Figure 6.2 B. The relative protein expression level of each protein is 
shown in Figure 6.2 C.  
To assess the effect of CPPs (R9 and 30Kc19) on soluble 
expression, transcription factors conjugated with R9 or 30Kc19 were 
expressed at 27 or 37℃ and the soluble fraction of each protein was 
analyzed by Western blot. As shown in Figure 6.2 C, 30Kc19 
promoted the production of Oct4 more as a soluble protein when 
expressed at either 27 or 37℃, while R9 did not influence Oct4 
solubilization. Sox2 and Klf4 were expressed as soluble proteins 
regardless of CPP type (Figure 6.2 C). While c-Myc was expressed 
as insoluble protein in any situation, another Myc family member, L-
Myc [88, 89], was highly expressed as a soluble protein when it was 
fused with 30Kc19 protein, whereas L-Myc alone showed a lower 
expression level and was not produced in soluble form. With R9, a 
small amount of L-Myc was expressed as soluble protein at 27℃. 
Overall, these results demonstrate that 30Kc19 protein enhanced the 
soluble expression of Oct4, Sox2, and L-Myc, which became 7.0, 2.9, 






Figure 6.2 Plasmid construction and soluble expression of 
transcription factors 
 
A. Transcription factors (Oct4, Sox2, c-Myc, Klf4, and L-Myc) 
were developed with and without nine arginine (R9) or 30Kc19. B. 
Comparison of soluble expression between transcription factors 
alone and transcription factors-30Kc19 at 37℃. E. coli lysates were 
analyzed by Western blot. T total lysate, S soluble fraction. C. The 
effect of a CPP for solubilization of transcription factors at 27 and 
37℃. Soluble fractions were analyzed by Western blot. The arrows 




6.3 Analysis of purified soluble transcription factors 
To further explore the role of the 30Kc19 protein conjugation on 
recombinant transcription factors, soluble transcription factors were 
purified using affinity chromatography. The size and amount of 
purified soluble proteins were confirmed by Coomassie blue staining 
(Figure 6.3 A) or Western blot (Figure 6.3 B). As shown in Figure 
6.3, each of the purified proteins was confirmed for their proper size. 
The results of purified Oct4 alone are not shown as there was 
insufficient amount of original soluble Oct4 as mentioned in Figure 
6.2. The amounts of purified soluble Sox2 and Klf4, without any 
conjugations, were also low. In contrast, a relatively high level of 
purified soluble Oct4-30Kc19, Sox2-30Kc19, and Klf4-30Kc19 
was observed, which coincides with the results in Figure 6.2. 
 
6.4 In vitro stability of soluble transcription factors 
The stability of transcription factors is important for effective gene 
regulation during cell culture. Here, we have investigated if 30Kc19 
protein conjugation contributes to the stability of transcription 
factors. To test the effect of 30Kc19 protein on the stability of 
soluble transcription factors in solution, seven purified soluble 
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transcription factors (Oct4-30Kc19, Sox2, Sox2-R9, Sox2-
30Kc19, Klf4, Klf4-R9, and Klf4-30Kc19) were added and 
incubated in the culture medium. Oct4 alone and Oct4-R9 were ruled 
out as they were expressed as an inclusion body resulting in 
negligible amount of soluble proteins. In serum-free medium, 10–15 
μg/ml of purified soluble transcription factors were incubated at 37℃ 
for 24 or 48 h before analysis. By using 30Kc19 protein as a fusion 
partner for transcription factors, we found that the stability of the 
soluble transcription factors was significantly increased (Figure 6.4). 
The levels of Sox2 and Klf4 proteins produced alone or with R9 
drastically decreased even within 24 h of incubation in medium, 
indicating poor stability. In contrast, all the transcription factors 
conjugated with 30Kc19 protein were stable for 48 h of 
incubation. Thus, it is conclusive that the conjugation of 30Kc19 









Figure 6.3 SDS-PAGE and Western blot analysis of purified 
soluble transcription factors  
 
Soluble transcription factors were purified using affinity 
chromatography. Purified proteins were separated by SDS-PAGE 
then visualized using Coomassie blue staining (A) or Western blot 










Figure 6.4 In vitro stability of soluble transcription factors. 
 
A. Purified Oct4-30Kc19 soluble protein was incubated in serum-
free media at 37℃ and analyzed using Western blot. The results of 
Oct4 alone and Oct4-R9 are not shown as they were expressed as 
aggregate forms. B, C. Purified Sox2 and Klf4 soluble protein were 
incubated with and without CPPs in serum free media at 37℃. After 
incubation for the indicated periods of time, the protein was analyzed 
by Western blot. Note that 30Kc19-conjugated transcription factors 




6.5 Cell penetration and intracellular stability of soluble 
transcription factors 
In our previous work, 30Kc19 protein delivered cargo protein into 
various cells and organs with maintaining its stability and causing low 
cytotoxicity [16]. Thus, the 30Kc19-conjugated transcription 
factors were selected for further study based on the following 
expectations: enhanced intracellular delivery and stability, and low 
cytotoxicity. First, the cell-penetration property of soluble 
transcription factors with 30Kc19 proteins was observed. To monitor 
the penetration of transcription factors into HDF cells, the proteins 
were labeled with Alexa Fluor® 488 and added to a culture medium 
at 20 μg/ml of the concentration. The fluorescence was observed in 
a live cell image using confocal microscopy. As shown in Figure 6.5 
A, the transcription factor with the 30Kc19 protein was observed in 
the cells within 30 min of incubation, and its intracellular 
concentration gradually increased over time. This indicates that 
30Kc19 protein conjugation successfully delivered transcription 
factors into cells.  
To confirm how long 30Kc19-conjugated transcription factors 
remain in the cells, intracellular stability was observed by 
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immunofluorescence analysis. We added 10 μg/ml of transcription 
factors to HDF cells for 24 and 48 h, respectively, and then the 
delivered proteins in the cells were detected with 
immunofluorescence. 30Kc19-conjugated transcription factors 
appeared to be stable inside the cells for up to 48 h (Figure 6.5 B). 
These results show that 30Kc19-conjugated transcription factors 
were stable in the cells and also agree with the in vitro results.  
 
6.6 Cytotoxicity of 30Kc19-conjugated transcription factors 
Subsequently, we evaluated if 30Kc19-conjugated transcription 
factor has cytotoxicity. HDF cells were treated with the same 
concentration of four conjugated transcription factors simultaneously 
for 12 and 24 h in a dose-dependent manner, and then cell viabilities 
were assessed using MTT assay (Figure 6.6). The concentration of 
each protein was 2, 5, 10, and 15 μg/ml, respectively. Even when 
the cells were treated with 60 μg/ml of four conjugated transcription 
factors (15 μg/ml each), there was no decrease in cell viability, 







Figure 6.5 Cell-penetrating property of 30Kc19-conjugated 
soluble transcription factors 
 
A. Proteins were labeled with Alexa Fluor 488 (green) for live cell 
imaging of 30Kc19-conjugated transcription factors (Oct4, Sox2, 
and Klf4). HDF cells were treated with labeled proteins in a time-
dependent manner and detected using confocal microscopy. B. 
Intracellular proteins after incubation were analyzed by 
immunofluorescence. Alexa Fluor 594 (red) antibody for target 
proteins was used for the detection of transcription factors in the 






Figure 6.6 Cellular toxicity test for transcription factors 
 
Cytotoxicity of 30Kc19-conjugated transcription factors. Four 
transcription factors were combined and cell viabilities were 
measured by MTT assay. HDF cells were treated with 2, 5, 10 and 
15 μg/ml of each protein (Oct4-30Kc19, Sox2-30Kc19, c-Myc-
30Kc19 and Klf4-30Kc19) for 12 and 24 h. Total protein= Oct4-
30Kc19 + Sox2-30Kc19 + c-Myc-30Kc19 + Klf4-30Kc19. Error 




6.7 Transcriptional activity of 30Kc19-conjugated Klf4 
Once introduced into cells, a transcription factor binds to its target 
DNA sequence in the nucleus for the control of transcription. Thus, 
we tested the transcriptional activity of a transcription factor-
conjugated with 30Kc19 protein compared with that conjugated with 
R9. Among transcription factors, Klf4 protein was chosen to confirm 
whether our recombinant proteins have transcriptional activity in the 
cells. When cells were treated with Klf4-30Kc19 protein, luciferase 
activity increased significantly depending on the concentration 
(Figure 6.6 A). Then, the transcriptional activity of Klf4-conjugated 
with 30Kc19 or R9 was compared. One micrograms per milliliter of 
each transcription factor was delivered, and transcriptional activities 
were measured 4 and 24 h after delivery. Klf4-30Kc19 increased 
transcriptional activity (p < 0.05) as time progressed (Figure 6.6 B). 
In contrast, there was no significant increase in transcriptional 
activity of Klf4-R9 (p = nonsignificant; NS). We can hypothesize 
that the higher transcriptional activity of Klf4-30Kc19 was due to 
the increased intracellular stability of Klf4 through 30Kc19 
conjugation. Immunocytochemistry of intracellular Klf4-30Kc19 and 
Klf4-R9 showed that Klf4-R9 level in cells drastically decreased 
87 
 
from 4 to 24 h after delivery (Figure 6.6 C). In contrast, there was a 
considerable amount of Klf4-30Kc19 still in the cells even at 24 h 
after delivery. This observation was similar to the in vitro stability 
results shown in Figure 6.4. Thus, it is obvious that 30Kc19 
conjugation enhanced transcriptional activity by increasing the 
intracellular stability of a transcription factor. 
 
6.8 Conclusions 
In this study, we have used 30Kc19 cell-penetrating protein as a 
novel fusion partner of transcription factors which can be used in 
protein-based iPSC generation. It was hypothesized that the 30Kc19 
protein has the potential to be developed as a fusion partner in the 
protein-based delivery of transcription factors for the regulation of 
gene expression, as it was shown to enhance the intracellular 
delivery as well as stability of its fusion protein. Interestingly, we 
have also found that the C-terminal fusion of the 30Kc19 protein 
promoted the soluble production of transcription factors, especially 
for Oct4 and L-Myc, while R9 did not.  
Also, we have shown that a 30Kc19 cell-penetrating protein 
simultaneously enhances soluble expression, stability, and the 
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transcriptional activity of transcription factors. Therefore, we 
propose that the multifunctional properties of 30Kc19 protein can be 
applied to general transcription factors and overcome several hurdles 








Figure 6.7 Effect of 30Kc19 conjugation on intracellular 
transcriptional activity of Klf4 protein  
 
A. Klf4-30Kc19 protein was delivered into transfected cells, and 
luciferase activity was measured after 4 h to determine 
transcriptional activity. *p < 0.05, **p < 0.01, ***p < 0.001 compared 
with the control group (n = 3). Error bars represent standard 
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deviation. B. One micrograms per milliliter of Klf4-R9 or Klf4-
30Kc19 proteins were added to cells. Luciferase activity of Klf4 was 
measured after 4 or 24 h incubation, respectively. (*p < 0.05, NS 
nonsignificant). C. Delivered Klf4 protein with 30Kc19 or R9 was 
analyzed by immunofluorescence. Green fluorescence represents the 
amount of Klf4 protein in the cells. Bright field (BF) images and 
fluorescence of nuclei (blue) images were merged and shown in the 
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Chapter 7. Direct conversion of fibroblasts to 
neuronal cells by 30Kc19-Ascl1-NLS-R9 protein 
 
7.1 Introduction 
Direct conversion, which is also known as transdifferentiation, has 
been actively developed due to rapid process with high efficiency. 
For cellular conversion, specific transcription factors were found, and 
they induced somatic cells to desired cells such as myoblasts [25], 
cardiomyocytes [26], pancreatic beta cells [27], or neurons [29]. 
For neuron conversion, recent work has shown that forced 
expression of a combination of 3 reprogramming factors, Ascl1, Brn2 
(also known as Pou3f2), Myt1l can efficiently convert mouse 
fibroblasts into functional induced neuronal cells (iNCs) [29]. A year 
later, the group then showed that using Ascl1 alone, generated 
functional iNCs from mouse and human fibroblasts (MEFs, HFFs), 
indicating that Ascl1 is the key driver for reprogramming to iNCs, 
and that Myt1l and Brn2 are primarily for maturation purpose [90]. 
In this study, protein is applied for direct conversion in order to 
avoid safety risk of virus. Ascl1 is selected for the transcription 
factor of neural conversion,  
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Here, we have used 30Kc19 protein as a novel fusion partner of 
reprogramming factor Ascl1 for generation of protein-induced 
neuronal cells (p-iNCs). 30Kc19 protein can be used to solve a 
problem that normally arise in the production of reprogramming 
factors, such as protein instability and low soluble expression [80]. 
The 30Kc19-based transcription factor will be anticipated to be the 
new strategy for protein-based direct conversion. 
 
7.2 Soluble expression of 30ANR protein 
It was reported that 30Kc19 protein enhances soluble expression 
of reprogramming factors [73]. Hence, the effect of 30Kc19 protein 
conjugation to reprogramming factor Ascl1 on soluble expression 
was determined 30Kc19-Ascl1-NLS-R9 (30ANR) and Ascl1-
NLS-R9 (ANR) vectors were constructed into the pET23a 
expression vector system between the NheI and XhoI site (Figure 
7.1 A). Each reprogramming protein was comprised with a T7 tag at 
the N-terminus for immunoassay. Both proteins were expressed in 
E. coli and then and the lysates were separated into soluble and 
insoluble fractions. Western blot analysis was performed by loading 
onto PAGE followed by an immunoblot against the His-tag, and 
94 
 
showed that fusion proteins were expressed correctly. Although 
30ANR protein with a size of about 60 kDa was present in both 
soluble and insoluble fractions, ANR protein with a size of 37 kDa 
was only found in the insoluble fraction and not in the soluble fraction 







Figure 7.1 Gene cloning and soluble expression of ANR and 
30ANR proteins 
A. Cloning of 30ANR and ANR in pET23a vector. B. Protein 
expression pattern. 30ANR was expressed both soluble and insoluble 
proteins, although ANR was expressed only insoluble protein. Total 




7.3 Purification, and in vitro stability of protein 
Soluble 30ANR protein was purified by Fast Protein Liquid 
Chromatography (FPLC), then analyzed by SDS-PAGE Coomassie 
blue staining (Figure 7.2 A) and Western blot analysis (Figure 7.2 
B). As demonstrated in Figure 7.2, 30Kc19 protein enhanced the 
soluble expression of the transcription factor, Ascl1. In previous 
study, 30Kc19 protein also enhanced the soluble expression of Oct4, 
Sox2, and L-myc proteins [73].  
The stability of reprogramming factor is vital for effective gene 
regulation during cell development. Hence, we investigated the effect 
of 30Kc19 protein on the stability of Ascl1 protein. Purified soluble 
30ANR protein was incubated in the serum-free culture medium at 
37℃ and 5% CO2 conditions and observed daily by Western blot 
analysis. ANR was ruled out as it was expressed as an inclusion body 
resulting in negligible amount of soluble proteins. By using 30Kc19 
protein as a fusion partner for reprogramming factor, we found that 
the stability of the soluble reprogramming factors was significantly 
maintained. After 2 days, 50% of the protein was detected and after 







Figure 7.2 Soluble protein purification and in vitro stability of 
30ANR protein 
 
A. Analysis of purified soluble protein using Coomassie blue staining, 
and Western blot (B). The band size is about 60 kDa. C. In vitro 
protein stability test in serum-free media at 37℃. The soluble 




7.4 Cell penetration 
Previously, we have observed delivery of cargo protein into various 
cells and organs using 30Kc19 protein [16]. Thus, soluble 30ANR 
protein was investigated for intracellular delivery. 50 μg/ml of 
fusion protein was added in mouse embryonic fibroblasts (MEFs) and 
incubated for 24 h at 37℃. Intracellular protein was analyzed by 
immunofluorescence using a confocal microscope. From Figure 7.3, 
30ANR protein was observed in the cells. Generally, transcription 
factors have controlled gene using their little amount, although the 
protein was in nucleus, the fluorescent was faint. However, there 
were previous study about transcription factor which had faint 












Figure 7.3 Cell penetration of 30ANR protein 
 
MEFs were incubated with 50 μg/ml of 30ANR protein for 24 h. 
After incubation, the cells were analyzed confocal microscopy. 






7.5 Cytotoxicity assay 
Cytotoxicity of 30ANR protein was measured using CCK-8 assay 
(Figure 7.4). 30ANR protein showed negligible difference in the 
viability of cells, indicating no cytotoxicity in MEF for 0 – 90 μg/ml 
protein. p > 0.05 meant that these are statistically insignificant. 
Therefore, treatment of 30ANR exhibited no cytotoxicity on MEFs. 
 
7.6 Generation of protein-induced neuronal cells (p-iNCs) 
Previous co-culture of mouse embryonic cells (MEFs) and glial 
cells (astrocytes) study [90] was used in this study (Figure 7.5 A). 
To distinct between MEFs and astrocytes, MEFs were stained with 
viral DsRed (Figure 7.5 B). For co-culture, 2 x 105 MEFs and 2 x 
104 astrocytes were seeded on 35 mm dish, and 50 μg/ml of proteins 
were treated on day 1 and 2 with DMEM-based MEF media. Then, 
from day 3, the cells were incubated with N3-based reprogramming 
media. In reprogramming media, proteins were treated to cells every 
3 days because proteins are remained more than 50% until day 3. At 









Figure 7.4 Cytotoxicity of 30ANR protein 
 
Proteins were added into cell media, and cytotoxicity was analyzed 
by CCK-8 assay after 24 h incubation. Error bars represent standard 









Figure 7.5 Schematic protocol for generating p-iNCs 
 
A. Timeline for generating p-iNCs. For 3 days, MEFs and astrocytes 
were incubated in DMEM-based MEF media. Then, the cells were 
incubated in N3-based reprogramming media. The cells were treated 
with 30ANR protein 6 times for 14 days. B. MEFs were stained by 
viral DsRed, and in co-culture MEFs and astrocytes were 




7.7 Cell morphology change  
From day 3, the changed cell morphologies were observed (Figure 
7.6). Cells, that were cultured with 30ANR protein, showed 
difference in the cell morphology in comparison with the cells that 
were cultured without protein (Figure 7.6 A). To distinguish MEFs 
and Astrocytes, co-culture cells were analyzed by fluorescence 
microscopy. From the fluorescence image, cells which had long ends 
similar to the neuronal cells were MEFs which were stained by DsRed 
(Figure 7.6 B). Thus, 30ANR protein could change the morphology 
of MEFs. 
 
7.8 Expression of neuronal biomarkers  
For analysis of cells, neuron-specific class III beta-tubulin (Tuj1) 
and microtubule associated protein 2 (MAP2) were used (Figure 7.7). 
At day 7, in the protein treated dish, Tuj1 and MAP2 positive p-iNCs 
were observed by immunocytochemistry. By the expression of 
DsRed, we confirmed that Tuj1 and MAP2 positive cells were from 
MEFs but not astrocytes (Figure 7.7 B). From the results, protein-







Figure 7.6 Cell morphology change during p-iNCs generation 
 
A. Co-culture of MEFs with astrocytes at day 0. 30ANR protein was 
added in the cells. B. Fluorescence image for co-culture dish. 
Neuronal morphology was observed in DsRed MEFs. Scale bar, 200 






Figure 7.7 Neuronal markers expression in p-iNCs 
A. MAP2 expression of p-iNCs at day 7. Scale bar, 200 μm. B. MAP2 
and Tuj1 neuronal markers were expressed in p-iNCs at day 7. DsRed 
indicated that the cells were from MEFs. Scale bar is 50 μm.   
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7.9 Neuronal gene expression in p-iNCs 
In order to test in more detail, we measured the endogenous gene 
levels of ASCL1, BRN2 and MYT1L in transitioning MEFs 7 or 14 
days after addition of 30ANR reprogramming protein (Figure 7.8). 
From the data of quantitative RT-qPCR, we found enhancement 
levels of ASCL1, BRN2 and MYT1L in the reprogramming protein-
added cells when compared to the controls. The expression levels of 
ASCL1 were increased 7.3 times in p-iNCs at day 7, and 13.1 times 
at day 14. In the case of Brn2, the expression levels were 10.7 or 
23.2 times higher in p-iNCs than control cells. The expression level 
of Myt1l at day 7 was 4.9 times, and 6.9 times higher than control 
cells at day 14. Therefore, p-iNCs showed higher neuronal gene 
expression than non-protein control cells.  
 
7.10 Electrophysiological recordings 
p-iNCs were then further characterized by electrophysiological 
recordings using whole cell patch-clamp analysis [91]. The neuron-
like cell was showed fast-inactivating inward and outward currents 
(Figure 7.9 A). Also, action potential was observed in cell (Figure 
7.9 B). These findings indicate that 30ANR protein could generate 
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neuronal cells. However, there was relatively small differences 
between control cells and p-iNCs. Further study could be carried out 









Figure 7.8 Expression of neuronal transcription factors in p-
iNCs 
 
ASCL1, BRN2 and MYT1L neuronal gene levels were quantified by 
RT-qPCR. *p < 0.05, **p < 0.01 compared with the control group (n 








Figure 7.9 Electrophysiological recordings 
 





In this study, 30Kc19 protein was applied as a fusion partner for 
soluble expression of a single reprogramming factor Ascl1 and was 
used for protein-based direct conversion of MEFs to induced 
neuronal cells (iNCs). We have previously observed that 30Kc19 
protein has the potential to be utilized as a fusion partner in the 
protein-based delivery of reprogramming factors for the regulation 
of gene expression [73]. Conjugating a cargo to the C-terminus of 
the 30Kc19 protein enhanced the soluble expression of Yamanaka 
factors (Oct4, Sox2, c-Myc, Klf4), as well as Ascl1 in our study, 
while R9 alone did not. This demonstrates that 30Kc19 protein is a 
promising candidate for soluble expression of reprogramming factors.  
With 30ANR protein, we generated p-iNCs successfully. p-iNCs 
had neuronal morphologies, and expressed neuronal markers, Tuj1 
and MAP2. Furthermore, from RT-qPCR data, p-iNCs expressed 
neuronal gene such as ASCL1, BRN2, and MYT1L. However, small 
increase in the sodium currents and action potentials demonstrated 
that 1 master factor-based p-iNCs may not be sufficient to generate 
a fully functional neuronal cells. It may be that longer period is 
necessary for the p-iNCs to be fully matured and have functional 
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electrophysiological properties. This protein method is anticipated to 
provide a safer generation of patient-specific human neurons for 











Overall discussion  






Chapter 8. Overall discussion and further suggestions 
Our group previously isolated 30Kc6 and 30Kc19 protein from 
silkworm hemolymph (SH), and have found the properties. 30Kc6 
inhibited apoptosis in many type of cells [9, 11]. We assume that 
30Kc6 prevents Bax to bind mitochondria [12]. As a result, by 
preventing to release cytochrome c, cellular apoptosis was inhibited. 
That is related to apoptosis of intrinsic mitochondrial pathway [92].  
Human pluripotent stem cells such as hESC and hiPSC have been 
induce a rapid apoptosis after apoptotic stimuli [93, 94]. In hESCs, 
unlike other mammalian cells, pre-activated Bax is existed at the 
Golgi. When the cells receive apoptotic stimuli, pre-activated Bax 
rapidly translocated to the mitochondria. Generally, pluripotent stem 
cells were required mechanical transfer due to preventing for 
apoptosis, and it was labor intensive and time-consuming [95, 96]. 
In dissociated pluripotent stem cells, myosin hyper-activation was 
occurred, and contraction-induced apoptosis is induced by activating 
caspase through mitochondria [97]. To use up-scaling and handle 
easy for human pluripotent stem cells, the study of facilitated 
expansion by enzymatic passaging methods has started in many 
groups [96, 98-102]. However, inhibition of rapid apoptosis is still a 
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big hurdle to overcome. In this study, we applied 30Kc6 anti-
apoptotic gene in hiPSCs, and observed hiPSC-30Kc6 had higher 
viability in single-cell enzymatic dissociation. Clear mechanism has 
to be further studied, but binding of 30Kc6 with Bax might prevent 
apoptosis in hiPSCs in a similar way in other mammalian cells. 
Furthermore, due to maintain of Bax at Golgi in hiPSCs, 30Kc6 is 
considered effective material to inhibit apoptosis specially in hiPSC 
or hESC. 
In apoptosis study, Bcl-2 family are well known as anti-apoptotic 
proteins by prevention for releasing of cytochrome c from 
mitochondria [103-105]. To be specific, BH4 domain which is an 
alpha-helix in Bcl-2 had a role for blocking apoptosis by interacting 
with Bax [106, 107]. There was a report about BHRF1 derived from 
Epstein-Barr virus, BHRF1 inhibited apoptosis using structural basis 
[108]. The structure of BHRF1 is alpha-helix as like BH4 domain, 
and it inhibited apoptosis by binding pro-apoptotic protein (Bid, 
Puma, or Bak). From these studies, we hypothesized that 30Kc6α 
which has structural similarity with other anti-apoptotic proteins, 
could play a role of apoptosis inhibition in 30Kc6. To observe anti-
apoptotic property, we truncated 30Kc6 to 30Kc6α and 30Kc6β, 
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then tested anti-apoptotic property of 30Kc6α. From the results, 
30Kc6α showed similar or higher anti-apoptotic effect than whole 
30Kc6. However, the effect was not regular in every cells due to 
different transfection efficiency. Thus, we tried to produce 30Kc6α 
as proteins, and 30Kc19 protein was conjugated for enhancement 
soluble expression and cell-penetration. 30Kc19-30Kc6α protein 
might be used in biotechnological industry to make valuable products.           
30Kc19 protein, one of the 30K members, was applied as a fusion 
partner for the production of recombinant transcription factors that 
are used for the generation of iPSCs. Even though the recombinant 
proteins were produced as soluble forms, the extracellular and 
intracellular instabilities of these proteins after treatment are a 
critical problem still requiring a solution. It was reported that unstable 
soluble proteins are aggregated easily during cell culture [80]. There 
were trials to increase the stability of proteins by adding supplements 
such as lipid-rich albumin or serum [109, 110]. We observed that 
30Kc19-conjugated transcription factors showed enhanced stability 
without additive materials to a culture medium. Previously, we 
reported that 30Kc19 protein increased enzyme stability via shielding 
effect; possibly by hydrophobic interaction [19]. The increased 
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stability of transcription factor is also considered to be due to the 
shielding effect of 30Kc19 protein. From luciferase and 
immunofluorescence assay, the results indicate that 30Kc19-
conjugated with transcription factors enhances the intracellular 
stability of the protein and thus provides more opportunities for the 
transcription factor to further penetrate into the nucleus to carry out 
its role in binding to target DNA to participate in transcription. To 
accomplish successful protein-based reprogramming, a significant 
amount of proteins is required [84]. However, because of a 
cytotoxicity hurdle, a small number of proteins (0.5–8 μg/ml) had to 
be added repeatedly, and 36 h was required between the cycles [61]. 
In the case of the 30Kc19-conjugated protein, even when the 
concentration of total proteins was 60 μg/ml, statistical differences 
in cytotoxicity were not observed. This demonstrates that 30Kc19 
protein is a nontoxic carrier for the delivery of transcription factors 
and enhances that stability of adjacent proteins. For reprogramming,  
optimal concentration of proteins has to be tested by considering with 
toxicity.   
Also, we used protein-based approach for generation of induced-
neuronal cells (p-iNCs) from co-culture of MEFs and glial 
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(astrocyte) cells [90]. Recent work has shown that mouse and human 
fibroblasts (MEFs, HFFs) and embryonic stem cells (mESCs, hESCs) 
can be directly reprogrammed into mature induced neuronal cells 
(iNCs) by forced expression of a single reprogramming factor Ascl1, 
and that Ascl1 is the key driver of iNC reprogramming [29, 111]. 
However, all methods to generate iNC require the use of genetic 
materials and/or potentially mutagenic molecules which could 
potentially be tumorigenic via integration of genetic material into the 
host cell genome [37, 75]. This protein-based approach is more 
practical and suitable method for clinical use due to low risks 
associated with tumorigenicity and genomic integration from the use 
of genetic materials such as DNA transfection and viruses. In this 
study, Ascl1 was conjugated with 30Kc19 protein. 30Kc19-Ascl1 
protein was enhanced soluble expression in E. coli. Also, 30Kc19 
protein could drag Ascl1 into cells, and induced neuronal cells. 
Further study could be carried out to analyze physical property of p-
iNCs. Also, investigation whether p-iNCs can be derived from human 
cells is required. This method is anticipated to provide a safer 
generation of patient-specific human neurons for future applications 
in regenerative medicine. 
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In the thesis, 30Kc6 anti-apoptotic protein and 30Kc19 cell-
penetrating protein were applied in cellular reprogramming. These 
new approaches could be a solution for the technical bottlenecks in 
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누에 체액 유래 30K 단백질은 다양한 기능을 가지는 것으로 알려
져 있다. 그 중에서도 세포의 생존율을 올리는 것이 맨 처음 알려졌는데, 
그 기능은 30K family (30Kc6, 30Kc12, 30Kc19, 30Kc21, 30Kc23) 
중 30Kc6가 담당 하는 것으로 알려졌다. 지난연구에서 30Kc6는 이를 
세포에 발현 시켰을 때, 세포의 성장을 돕고 세포자멸 (apoptosis) 을 
막아주는 기능을 보였다. 이와 같은 결과는 세포에서 항체 및 다양한 단
백질 생산 효율을 올리는데 기여할 수 있었다. 30Kc6의 세포자멸 억제 
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기작은 미토콘드리아에 Bax가 결합하지 못하도록 하는 것인데, 30Kc6
를 세포에 발현시킨 후 세포자멸을 유도하였을 때, Bax가 미토콘드리아
에 결합하지 못하여 cytochrome c가 나오지 못하는 것을 발견할 수 있
었다. 또 다른 30K 단백질 중 하나인 30Kc19 단백질은 세포 투과 펩
타이드 (Pep-c19) 를 가지고 있어 세포 안으로 들어가며, 이 때 단백
질 이합체를 형성하는 것으로 알려졌다. 30Kc19 단백질은 또한 효소와 
같은 단백질의 안정성을 올릴 수 있었는데, 이는 BSA와 같이 주변을 감
싸 외부 공격으로부터 단백질을 보호하는 역할을 하는 것으로 고려된다. 
또한 최근에는 30Kc19이 결합된 단백질의 수용성 생산을 늘리는 것을 
밝혔다.  
이 연구의 목적은 30K 단백질의 이러한 특성들을 이용하여, 줄기세
포 연구가 가지는 한계를 극복하고자 하는데 있다. 먼저, 배양 과정이 
노동집약적이고 단일 세포로 떨어졌을 때 빠른 세포자멸이 일어나는 역
분화줄기세포에 30Kc6를 적용하여, 단일세포에서 세포 생존율을 올렸다. 
이러한 특징을 보기에 앞서 30Kc6가 들어가도 역분화줄기세포의 다능
성에 변화가 없는지를 확인하였고, 세가지 배엽으로 분화가 가능한지를 
보았다. 그 결과 30Kc6를 가지는 역분화줄기세포는 줄기세포의 특징은 
잃지 않으면서, 단일세포에서 세포자멸이 억제되는 것을 확인하였다.  
다음으로 30Kc6의 세포자멸 억제효과가 N-terminal의 30Kc6α
에 의한 것이라는 것을 밝혔다. 대표적인 세포자멸 억제 단백질인 Bcl2
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의 기작을 보았을 때 알파나선 구조가 Bax 단백질에 결합하여, Bax의 
활성을 저해하는 것으로 알려졌다. 이러한 문헌을 토대로 30Kc6의 알파
나선 구조 (30Kc6α)가 세포자멸 억제 효과를 낼 것으로 기대하였다. 
세포에 30Kc6α를 도입한 결과 해당 세포는 세포자멸 억제 효과가 있
는 것으로 보였으며, 이는 30Kc6를 도입한 것보다도 더 좋은 효과였다. 
따라서 30Kc6의 세포자멸 억제 효과는 30Kc6α가 담당하는 것으로 결
론을 지을 수 있었으며, 30Kc6α를 단백질로 생산하기 위해 세포 투과 
30Kc19 단백질을 유전적으로 결합시켜 생산하였다. 그 결과 30K19-
30Kc6α 단백질은 수용성 형태로 생산이 되었으며, 세포 투과기능이 있
는 것으로 보였다. 또한 재조합 단백질을 세포에 처리하고 세포자멸을 
유도하였을 때 단백질을 처리한 농도에 비례하여 세포 생존율이 올라가
는 것을 보았다.  
세포 투과 단백질인 30Kc19은 세포 리프로그래밍을 위한 전사인자
들 (Oct4, Sox2, c-Myc, Klf4, L-Myc) 에 유전적으로 결합되어 생산
되었다. 전사인자 단독만으로는 수용성으로 생산되지 않던 Oct4와 L-
Myc단백질도 30Kc19이 결합된 후 수용성으로 생산이 되었다. 뿐만 아
니라 30Kc19이 결합된 전사인자들은 37℃에서 좀 더 나은 안정성을 
보였다. 세포 리프로그래밍에서 단백질의 대량생산과 안정성 문제를 해
결하는 것은 매우 큰 과제이기 때문에, 30Kc19 단백질을 이용하여 이 
부분에서 효과를 본 것은 매우 큰 의미가 있다. 마지막으로 30Kc19과 
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결합된 전사인자는 세포의 핵 안으로 들어가 전사 단백질의 활동을 할 
수 있음을 보았다. 
전사인자가 30Kc19단백질과 결합하여 수용성 생산량이 늘고 세포
로 잘 들어가는 것을 확인한 후, 우리는 신경세포를 유도하는 전사인자
인 Ascl1을 30Kc19에 결합하여 세포의 직접 변환을 시도하였다. 생산
된 30Kc19-Ascl1-NLS-R9 단백질은 세포에 잘 들어가서 전사를 조
절하여, 피부세포를 신경세포로 직접변환을 시켰다. 단백질로 유도된 신
경세포는 신경세포 유전자와 단백질을 가지는 것으로 확인되었다. 
본 연구에서는 30K 단백질 중 세포자멸 억제 단백질인 30Kc6와 
세포 투과 단백질인 30Kc19을 이용하여 이를 줄기세포에 적용하였으며, 
줄기세포연구가 가지는 여러가지 한계들을 해결할 수 있었다. 앞으로도 
이러한 30K 단백질은 줄기세포 뿐 아니라 제약산업, 화장품 산업 등에
서 여러가지 공정기술 개발에 유용하게 사용될 수 있을 것으로 기대된다. 
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